Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2001 Feb;62(2):87-91.
doi: 10.4088/jcp.v62n0203.

Delusionality and response to open-label fluvoxamine in body dysmorphic disorder

K A Phillips  1 , S L McElroy, M M Dwight, J L Eisen, S A Rasmussen
Affiliations
Clinical Trial

Delusionality and response to open-label fluvoxamine in body dysmorphic disorder

K A Phillips et al. J Clin Psychiatry. 2001 Feb.

Abstract

Background: Available data suggest that the delusional variant of body dysmorphic disorder (BDD), a type of delusional disorder, may respond to serotonin reuptake inhibitors (SRIs) and that delusionality (lack of insight) in BDD may improve with SRI treatment. However, this research has been hampered by the lack of a reliable and valid scale to assess delusionality.

Method: Thirty subjects (21 women, 9 men; mean age = 33.3 +/- 9.0 years) with DSM-IV BDD were prospectively treated with open-label fluvoxamine for 16 weeks. Subjects were assessed at regular intervals with the Brown Assessment of Beliefs Scale (BABS), the Yale-Brown Obsessive Compulsive Scale Modified for BDD (BDD-YBOCS; a measure of BDD severity), and other instruments. The BABS is a reliable and valid 7-item, semistructured, clinician-administered scale that assesses current delusionality.

Results: In this prospective, open-label study, 63% of BDD subjects responded to fluvoxamine. Delusional and nondelusional subjects had similar improvement in BDD symptoms. In addition, insight significantly improved in both delusional and nondelusional subjects. Baseline BABS scores did not contribute significantly to endpoint BDD-YBOCS scores in a regression analysis.

Conclusion: Degree of delusionality did not predict fluvoxamine response, and delusionality significantly improved. These findings are preliminary and require confirmation in controlled trials. The implications of these findings for other types of delusions requires investigation.

PubMed Disclaimer

References

    1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV) 4. Washington, DC: American Psychiatric Association; 1994.
    1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5) 5. Washington, DC: American Psychiatric Publishing; 2013.
    1. Buhlmann U, Glaesmer H, Mewes R, Fama JM, Wilhelm S, Brähler E, Rief W. Updates on the prevalence of body dysmorphic disorder: A population-based survey. Psychiatry Research. 2010;178:171–175. doi: 10.1016/j.psychres.2009.05.002. - DOI - PubMed
    1. Conroy M, Menard W, Fleming-Ives K, Modha P, Cerullo H, Phillips KA. Prevalence and clinical characteristics of body dysmorphic disorder in an adult inpatient setting. General Hospital Psychiatry. 2008;30:67–72. - PMC - PubMed
    1. Davidson JRT, Miner CM, De Veaugh-Geiss J, Tupler LA, Colket JT, Potts NL. The Brief Social Phobia Scale: A psychometric evaluation. Psychological Medicine. 1997;27:161–166. doi: 10.1017/S0033291796004217. - DOI - PubMed

Substances